How to "choosebetweenamab" for severe asthma, Mepolizumab is as effective as Omalizumab in improving asthma symptom control, as measured by the asthma control questionnaire (ACQ5), for patients with severe allergic and eosinophilic asthma
Phase of Trial: Phase IV
Latest Information Update: 16 Jul 2019
Price : $35 *
At a glance
- Drugs Mepolizumab (Primary) ; Omalizumab
- Indications Asthma
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 30 Nov 2018 Status changed from not yet recruiting to recruiting.
- 23 Aug 2018 Planned initiation date changed from 4 Jun 2018 to 10 Sep 2018.
- 22 May 2018 New trial record